(Reuters) -Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates ...

The ABBOTT PRISM System is an automated immunoassay analyzer designed to perform Chemiluminescent immunoassay (ChLIA) technology. The ABBOTT PRISM performs batch/continuous access and STAT ...

Sales growth in the medical devices segment drove Abbott Laboratories’ expectations-beating revenue in the past financial quarter as the company faces lower demand for COVID-19 tests ...

Abbott stock rose Wednesday after the health care giant narrowly beat Wall Street's third-quarter expectations and raised the midpoint of its earnings outlook. Please watch the video at Investors ...

Abbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical devices. Sales were also higher at its pharmaceutical unit, but fell at its diagnostics and ...

Abbott announced today that the FDA said users can wear the FreeStyle Libre 2 and 3 CGMs during common imaging procedures.

In closing arguments on Wednesday, plaintiff's lawyer Timothy Cronin asked jurors for $6 billion in punitive damages.

Juries hit Mead Johnson and Abbott Laboratories with verdicts of $60 million and $495 million respectively earlier this year ...

Abbott and Reckitt unit Mead Johnson are not responsible for a young boy's debilitating intestinal disease, a jury found on ...

The US Food and Drug Administration has okayed removal of the contraindication for use during CT and MRI under certain ...

Trends To Watch Out For In Q3 Abbott should see steady growth across its segments. While the Nutrition segment should benefit from market share gains for its baby formula products, medical devices ...

The company's medical devices unit generated $4.75 billion in sales for the third quarter, above analysts' average estimate of $4.68 billion, according to data compiled by LSEG. Overall ...